Apellis’ application to market its complement C3 inhibitor Syfovre (pegcetacoplan) to treat geographic atrophy (GA) – a sight-robbing condition that accompanies age-related macular ...

Levels of FI achieved in VH from FOCUS subjects were then used in an in vitro simulated human vitreous complement activation assay, to gain insights on the therapeutic potencies of FI, C3 inhibitor ...

Apellis Pharmaceuticals (APLS) receives FDA approval of Syfovree for the treatment of geographic atrophy.

We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against ...

Apellis reported total revenues of $397 million for 2023, a sharp increase from $75 million in 2022, driven by SYFOVRE's launch and ongoing sales of EMPAVELI for paroxysmal nocturnal ...

According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023. Through 2027, it is projected to grow at a ...

Both Syfovre and Izervay must be injected directly into the eye once per month, or every other month, on an ongoing basis. They prevent damage to retinal cells by calming the immune response and ...

Earlier this year, Apellis Pharma became the first company to claim FDA approval for a drug to treat the condition, Syfovre (pegcetacoplan), which also targets the complement system. Syfovre needs ...

Revenue for the quarter came in at $95M... ByInvesting.com • 31 Jul 2023 Apellis Provides Update on Review of Rare Safety Events with SYFOVRE Apellis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:APLS) (“the ...

The second, approved in February 2023, is Syfovre for the treatment of Geographic Atrophy (GA). Syfovre has shown compelling data out to 36 months and its launch has been going extraordinarily well.